ZIA BC 011660 (ZIA) | |||
---|---|---|---|
Title | Development of fully-human anti-CD30 chimeric antigen receptors | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Kochenderfer, James | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $217,789 | Project Dates | 01/01/2014 - 00/00/0000 |
Fiscal Year | 2015 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Bioengineering (30.0%) Cancer (100.0%) Gene Therapy (100.0%) Gene Therapy Clinical Trials (100.0%) |
Hodgkins disease (80.0%) Non Hodgkins Lymphoma (20.0%) |
||
Research Type | |||
Systemic Therapies - Discovery and Development Systemic Therapies - Clinical Applications |
|||
Abstract | |||
We have designed 4 different single chain Fv molecules as antigen-recognition domains for anti-CD30 CARs and compared CARs with these different scFvs in vitro. We selected the optimal scFv, and tested it in different CAR designs in vitro and in mouse tumor models. We have identified an optimal scFv and CAR design for further development. This design is undergoing more in vitro and murine studies while simultaneous work progresses on preparing a clinical-grade lentiviral vector encoding this CAR. We are also starting work on a clinical protocol for a clinical trial of the fully-human anti-CD30 CAR that is planned to start in 2016. |